Drug Search Results
More Filters [+]

ST-067

Alternative Names: st-067, st 067, st067
Latest Update: 2024-07-09
Latest Update Note: Clinical Trial Update

Product Description

Simcha IL-18 is developing ST-067 as a treatment for relapsed or refractory solid tumors. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04787042)

Mechanisms of Action: IL18 Activator

Novel Mechanism: Yes

Modality: Cytokine

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Simcha IL-18
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ST-067

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Colorectal Cancer|Head and Neck Cancer|Melanoma|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ST-067-001

P2

Recruiting

Head and Neck Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Colorectal Cancer|Triple Negative Breast Cancer|Melanoma|Renal Cell Carcinoma

2024-06-30

57%

Recent News Events